Skip to main content

Table 1 Inclusion and exclusion criteria

From: Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study

Inclusion criteria:

 • Trial assessed an intervention for efficacy in the treatment or prevention of COVID-19 infection and subsequent acute disease.a

 • Trial included a completion date, or primary completion date, on or before 30 June 2021

Exclusion criteria:

 • Registration was found, at any time, to indicate that the trial was withdrawn before enrollment and therefore never occurred

 • Registration prior to 1 January 2020

 • Trial exclusively on symptomatic treatment of COVID-19 disease side-effects only (post hoc)

 • Trial on rehabilitation after acute disease or treatment of post-COVID-19 disease (post hoc)

  1. aDuring final data collection, two main clarifications were necessary for this criteria: First, we excluded trials with primary outcomes that examined only the safety of an intervention; Second, studies examining inflammatory biomarkers (e.g., D-Dimer, C-Reactive Protein) were counted as efficacy outcomes
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us